TY - JOUR
T1 - HIV testing in patients with cancer at the initiation of therapy at a large US Comprehensive Cancer Center
AU - Hwang, Jessica P.
AU - Granwehr, Bruno P.
AU - Torres, Harrys A.
AU - Suarez-Almazor, Maria E.
AU - Giordano, Thomas P.
AU - Barbo, Andrea G.
AU - Lin, Heather Y.
AU - Fisch, Michael J.
AU - Chiao, Elizabeth Y.
N1 - Publisher Copyright:
© 2015 by American Society of Clinical Oncology.
PY - 2015/9
Y1 - 2015/9
N2 - Purpose: To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. Methods: We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. Results: Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. Conclusion: The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
AB - Purpose: To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. Methods: We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. Results: Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. Conclusion: The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
UR - http://www.scopus.com/inward/record.url?scp=84976618692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976618692&partnerID=8YFLogxK
U2 - 10.1200/JOP.2015.005116
DO - 10.1200/JOP.2015.005116
M3 - Article
C2 - 26243649
AN - SCOPUS:84976618692
SN - 1554-7477
VL - 11
SP - 384
EP - 390
JO - Journal of oncology practice
JF - Journal of oncology practice
IS - 5
ER -